Julian R Molina
Overview
Explore the profile of Julian R Molina including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
103
Citations
6198
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Lozachmeur A, Danek T, Yang Q, Rosasco M, Welch J, Go W, et al.
NPJ Precis Oncol
. 2024 Aug;
8(1):174.
PMID: 39103508
To enable interrogation of tumor HLA LOH as a clinical diagnostic for precision oncology, we developed and validated an assay that detects HLA LOH within the context of an FDA-approved...
2.
Baral B, Suleiman R, Fazer-Posorske C, Ma D, McGarrah P, Thome S, et al.
Head Neck
. 2024 Jul;
46(10):E84-E90.
PMID: 39032143
Background: Head and neck cancers (HNC) present diagnostic challenges due to multifocal disease manifestations, posing difficulties in distinguishing between metastatic disease and second primary malignancies (SPM). This complexity underscores the...
3.
Naso J, Vrana J, Koepplin J, Molina J, Roden A
Cancers (Basel)
. 2023 May;
15(8).
PMID: 37190202
Thymic carcinoma is an aggressive malignancy that can be challenging to distinguish from thymoma using histomorphology. We assessed two emerging markers for these entities, EZH2 and POU2F3, and compared them...
4.
5.
Thirusangu P, Ray U, Sarkar Bhattacharya S, Oien D, Jin L, Staub J, et al.
Oncogene
. 2022 Nov;
42(1):79-82.
PMID: 36443398
No abstract available.
6.
Yang F, Wang Y, Tang L, Mansfield A, Adjei A, Leventakos K, et al.
Front Oncol
. 2022 Sep;
12:955440.
PMID: 36052255
Background: Immune checkpoint inhibitors (ICIs) have demonstrated remarkable efficacy in non-small cell lung cancer (NSCLC). However, only a minority of NSCLC patients benefit from ICIs, and whether the magnitude of...
7.
Thirusangu P, Ray U, Sarkar Bhattacharya S, Oien D, Jin L, Staub J, et al.
Oncogene
. 2022 Jul;
41(33):4003-4017.
PMID: 35804016
PFKFB3 (6-phosphofructo-2-kinase) is the rate-limiting enzyme of glycolysis and is overexpressed in several human cancers that are associated with poor prognosis. High PFKFB3 expression in cancer stem cells promotes glycolysis...
8.
Sarkar Bhattacharya S, Thirusangu P, Jin L, Staub J, Shridhar V, Molina J
Br J Cancer
. 2022 Jul;
127(7):1352-1364.
PMID: 35794237
Background: Malignant pleural mesothelioma (MPM) is an aggressive neoplasm and often acquires chemoresistance by increasing stemness in tumour tissue, thereby generating cancer stem cells (CSCs). CSCs escape treatment by deploying...
9.
10.
Yang F, Wang J, Wang Y, Liu B, Molina J
Cancers (Basel)
. 2022 Jan;
14(1).
PMID: 35008273
Immune checkpoint inhibitors (ICIs) targeting programmed cell death protein 1 (PD-1)/programmed death-ligand 1 (PD-L1) have dramatically changed the landscape of cancer therapy. Both remarkable and durable responses have been observed...